Fierce Pharma Asia—Takeda's cancer drug withdrawal; Kyowa Kirin's gene therapy buy; Biogen's biosim nod

06 Oct 2023
www.fiercepharma.com
AcquisitionDrug ApprovalPhase 3IPOGene Therapy
Fierce Pharma Asia—Takeda's cancer drug withdrawal; Kyowa Kirin's gene therapy buy; Biogen's biosim nod
Preview
Source: FiercePharma
Takeda's Exkivity market withdrawal, Kyowa Kirin's acquisition of Orchard Therapeutics and Biogen's Actemra biosimilar approval made our news this week.
Takeda will withdraw lung cancer drug Exkivity after a confirmatory trial failure. Kyowa Kirin is buying gene therapy biotech Orchard Therapeutics. Biogen's biosimilar version of Roche's Actemra, bought from Bio-Thera Solutions, won an FDA nod. And more.
1. Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop
Takeda will pull Exkivity from the market in the U.S. and beyond. The drug won an accelerated approval in 2021 for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. But the phase 3 EXCLAIM-2 confirmatory trial in the first-line setting was a blunder. Exkivity failed as a monotherapy, just as Johnson & Johnson’s rival therapy Rybrevant succeeded in a combination with chemotherapy.
2. Orchard lands $387M Kyowa buyout, reaping harvest of US gene therapy progress
Kyowa Kirin is paying $387.4 million upfront to purchase Orchard Therapeutics, which has a gene therapy for early-onset metachromatic leukodystrophy approved in Europe and under review at the FDA. Orchard investors will get an additional $1 per share if the FDA approves the med. After some clinical setbacks, Kyowa CEO Masashi Miyamoto recently said the company was working on acquisitions.
3. Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
The FDA has approved the first biosimilar to Roche’s blockbuster autoimmune drug Actemra. The copycat, now branded as Tofidence, will be marketed by Biogen. The company got the drug in 2021 from Chinese company Bio-Thera Solutions by paying $30 million upfront. The approval comes as Biogen conducts a strategic review of its biosimilar franchise.
4. Adlai, building on the ashes of Novartis' failure, raises $57.5M IPO to run phase 3 cancer trial
Chinese-American biotech Adlai Nortye has raised $97.5 million through a Nasdaq IPO and private placement, and traded down 33% on its first day. The company has a Novartis castoff, a PI3K inhibitor called buparlisib, serving as its lead candidate. The drug is in pivotal testing in head and neck cancer. Novartis sold the drug for just $9.5 million upfront after seeing safety issues in a phase 3 breast cancer study.
5. In selling 3 businesses, Viatris bids adieu to 10 manufacturing plants, 6,000 employees
Viatris is shedding some over-the-counter, women’s health and active pharmaceutical ingredient assets for more than $3 billion. In one deal, Viatris has agreed to sell its API business in India to IQuest Enterprises. The deal features six manufacturing sites and an R&D lab.
Other News of Note
6. Flooding halts manufacturing at Alembic Pharmaceuticals plant in India
7. Lokavant snares $8M investment to expand its presence in Asia-Pacific region
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.